Literature DB >> 21366961

The sugar ring conformation of 4'-ethynyl-2-fluoro-2'-deoxyadenosine and its recognition by the polymerase active site of HIV reverse transcriptase.

K A Kirby1, K Singh, E Michailidis, B Marchand, E N Kodama, N Ashida, H Mitsuya, M A Parniak, S G Sarafianos.   

Abstract

4' Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) is the most potent inhibitor of HIV reverse transcriptase (RT). We have recently named EFdA a Translocation Defective RT Inhibitor (TDRTI) because after its incorporation in the nucleic acid it blocks DNA polymerization, primarily by preventing translocation of RT on the template/primer that has EFdA at the 3'-primer end (T/PEFdA). The sugar ring conformation of EFdA may also influence RT inhibition by a) affecting the binding of EFdA triphosphate (EFdATP) at the RT active site and/or b) by preventing proper positioning of the 3'-OH of EFdA in T/PEFdA that is required for efficient DNA synthesis. Specifically, the North (C2'-exo/C3'-endo), but not the South (C2'-endo/C3'-exo) nucleotide sugar ring conformation is required for efficient binding at the primer-binding and polymerase active sites of RT. In this study we use nuclear magnetic resonance (NMR) spectroscopy experiments to determine the sugar ring conformation of EFdA. We find that unlike adenosine nucleosides unsubstituted at the 4'-position, the sugar ring of EFdA is primarily in the North conformation. This difference in sugar ring puckering likely contributes to the more efficient incorporation of EFdATP by RT than dATP. In addition, it suggests that the 3'-OH of EFdA in T/PEFdA is not likely to prevent incorporation of additional nucleotides and thus it does not contribute to the mechanism of RT inhibition. This study provides the first insights into how structural attributes of EFdA affect its antiviral potency through interactions with its RT target.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21366961      PMCID: PMC3119259     

Source DB:  PubMed          Journal:  Cell Mol Biol (Noisy-le-grand)        ISSN: 0145-5680            Impact factor:   1.770


  30 in total

1.  Chemistry and anti-HIV properties of 2'-fluoro-2',3'-dideoxyarabinofuranosylpyrimidines.

Authors:  M A Siddiqui; J S Driscoll; V E Marquez; J S Roth; T Shirasaka; H Mitsuya; J J Barchi; J A Kelley
Journal:  J Med Chem       Date:  1992-06-12       Impact factor: 7.446

2.  Adenosine deaminase prefers a distinct sugar ring conformation for binding and catalysis: kinetic and structural studies.

Authors:  H Ford; F Dai; L Mu; M A Siddiqui; M C Nicklaus; L Anderson; V E Marquez; J J Barchi
Journal:  Biochemistry       Date:  2000-03-14       Impact factor: 3.162

3.  Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel.

Authors:  Scott M Hammer; Michael S Saag; Mauro Schechter; Julio S G Montaner; Robert T Schooley; Donna M Jacobsen; Melanie A Thompson; Charles C J Carpenter; Margaret A Fischl; Brian G Gazzard; Jose M Gatell; Martin S Hirsch; David A Katzenstein; Douglas D Richman; Stefano Vella; Patrick G Yeni; Paul A Volberding
Journal:  Top HIV Med       Date:  2006 Aug-Sep

4.  Interactions of conformationally biased north and south 2'-fluoro-2', 3'-dideoxynucleoside 5'-triphosphates with the active site of HIV-1 reverse transcriptase.

Authors:  L Mu; S G Sarafianos; M C Nicklaus; P Russ; M A Siddiqui; H Ford; H Mitsuya; R Le; E Kodama; C Meier; T Knispel; L Anderson; J J Barchi; V E Marquez
Journal:  Biochemistry       Date:  2000-09-19       Impact factor: 3.162

5.  Mechanism of inhibition of HIV-1 reverse transcriptase by 4'-Ethynyl-2-fluoro-2'-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor.

Authors:  Eleftherios Michailidis; Bruno Marchand; Eiichi N Kodama; Kamlendra Singh; Masao Matsuoka; Karen A Kirby; Emily M Ryan; Ali M Sawani; Eva Nagy; Noriyuki Ashida; Hiroaki Mitsuya; Michael A Parniak; Stefan G Sarafianos
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

6.  Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance.

Authors:  H Huang; R Chopra; G L Verdine; S C Harrison
Journal:  Science       Date:  1998-11-27       Impact factor: 47.728

Review 7.  Antimicrobial strategies: inhibition of viral polymerases by 3'-hydroxyl nucleosides.

Authors:  Jerome Deval
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 8.  Anti-HIV drugs.

Authors:  E De Clercq
Journal:  Verh K Acad Geneeskd Belg       Date:  2007

Review 9.  Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors.

Authors:  Nicolas Sluis-Cremer; Gilda Tachedjian
Journal:  Virus Res       Date:  2008-03-26       Impact factor: 3.303

10.  Synthesis, solution conformation and anti-HIV activity of novel 3'-substituted-2',3'-dideoxy-5-hydroxymethyluridines and their 4,5-substituted analogues.

Authors:  Jaroslaw Poznanski; Maria Bretner; Tadeusz Kulikowski; Jan Balzarini; Arthur Van Aerschot; Erik De Clercq
Journal:  Antivir Chem Chemother       Date:  2003-05
View more
  15 in total

1.  Probing the molecular mechanism of action of the HIV-1 reverse transcriptase inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) using pre-steady-state kinetics.

Authors:  Yagmur Muftuoglu; Christal D Sohl; Andrea C Mislak; Hiroaki Mitsuya; Stefan G Sarafianos; Karen S Anderson
Journal:  Antiviral Res       Date:  2014-03-12       Impact factor: 5.970

2.  SAMHD1 has differential impact on the efficacies of HIV nucleoside reverse transcriptase inhibitors.

Authors:  Andrew D Huber; Eleftherios Michailidis; Megan L Schultz; Yee T Ong; Nicolin Bloch; Maritza N Puray-Chavez; Maxwell D Leslie; Juan Ji; Anthony D Lucas; Karen A Kirby; Nathaniel R Landau; Stefan G Sarafianos
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

3.  Evaluation of Combinations of 4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine with Clinically Used Antiretroviral Drugs.

Authors:  Atsuko Hachiya; Aaron B Reeve; Bruno Marchand; Eleftherios Michailidis; Yee Tsuey Ong; Karen A Kirby; Maxwell D Leslie; Shinichi Oka; Eiichi N Kodama; Lisa C Rohan; Hiroaki Mitsuya; Michael A Parniak; Stefan G Sarafianos
Journal:  Antimicrob Agents Chemother       Date:  2013-06-24       Impact factor: 5.191

4.  Mechanism of interaction of human mitochondrial DNA polymerase γ with the novel nucleoside reverse transcriptase inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine indicates a low potential for host toxicity.

Authors:  Christal D Sohl; Kamlendra Singh; Rajesh Kasiviswanathan; William C Copeland; Hiroaki Mitsuya; Stefan G Sarafianos; Karen S Anderson
Journal:  Antimicrob Agents Chemother       Date:  2011-12-12       Impact factor: 5.191

5.  Synthesis and evaluation of the anti-hepatitis B virus activity of 4'-Azido-thymidine analogs and 4'-Azido-2'-deoxy-5-methylcytidine analogs: structural insights for the development of a novel anti-HBV agent.

Authors:  Kengo Onitsuka; Ryoh Tokuda; Nobuyo Kuwata-Higashi; Hiroki Kumamoto; Manabu Aoki; Masayuki Amano; Satoru Kohgo; Debananda Das; Kazuhiro Haraguchi; Hiroaki Mitsuya; Shuhei Imoto
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2019-09-12       Impact factor: 1.381

6.  Physiological Mg2+ Conditions Significantly Alter the Inhibition of HIV-1 and HIV-2 Reverse Transcriptases by Nucleoside and Non-Nucleoside Inhibitors in Vitro.

Authors:  Vasudevan Achuthan; Kamlendra Singh; Jeffrey J DeStefano
Journal:  Biochemistry       Date:  2016-12-27       Impact factor: 3.162

7.  Derivatives of mesoxalic acid block translocation of HIV-1 reverse transcriptase.

Authors:  Jean A Bernatchez; Rakesh Paul; Egor P Tchesnokov; Marianne Ngure; Greg L Beilhartz; Albert M Berghuis; Rico Lavoie; Lianhai Li; Anick Auger; Roman A Melnyk; Jay A Grobler; Michael D Miller; Daria J Hazuda; Sidney M Hecht; Matthias Götte
Journal:  J Biol Chem       Date:  2014-10-29       Impact factor: 5.157

8.  Balancing antiviral potency and host toxicity: identifying a nucleotide inhibitor with an optimal kinetic phenotype for HIV-1 reverse transcriptase.

Authors:  Christal D Sohl; Rajesh Kasiviswanathan; Jiae Kim; Ugo Pradere; Raymond F Schinazi; William C Copeland; Hiroaki Mitsuya; Masanori Baba; Karen S Anderson
Journal:  Mol Pharmacol       Date:  2012-04-18       Impact factor: 4.436

9.  Development of Human Immunodeficiency Virus Type 1 Resistance to 4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine Starting with Wild-Type or Nucleoside Reverse Transcriptase Inhibitor-Resistant Strains.

Authors:  Maria E Cilento; Aaron B Reeve; Eleftherios Michailidis; Tatiana V Ilina; Eva Nagy; Hiroaki Mitsuya; Michael A Parniak; Philip R Tedbury; Stefan G Sarafianos
Journal:  Antimicrob Agents Chemother       Date:  2021-09-13       Impact factor: 5.191

10.  Effects of substitutions at the 4' and 2 positions on the bioactivity of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.

Authors:  Karen A Kirby; Eleftherios Michailidis; Tracy L Fetterly; Musetta A Steinbach; Kamalendra Singh; Bruno Marchand; Maxwell D Leslie; Ariel N Hagedorn; Eiichi N Kodama; Victor E Marquez; Stephen H Hughes; Hiroaki Mitsuya; Michael A Parniak; Stefan G Sarafianos
Journal:  Antimicrob Agents Chemother       Date:  2013-10-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.